Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathwayBrandon W. Higgs, Steven A. Greenberg, Bahija Jallal et al.|Annals of the Rheumatic Diseases|2011Cited by 412
Type I Interferon: Potential Therapeutic Target for Psoriasis?Yihong Yao, Bahija Jallal|PLoS ONE|2008Cited by 308
Type I interferon–inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositisRonan J. Walsh, Steven A. Greenberg, Sek Won Kong et al.|Arthritis & Rheumatism|2007Cited by 304
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patientsBrandon W. Higgs, Yihong Yao, Wei Zhu et al.|Annals of the Rheumatic Diseases|2013Cited by 168
A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growthKatie Streicher, Yandan Yao, Wei Zhu et al.|Oncogene|2011Cited by 135